Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Forensic Science International

• Publication date

  2005-10-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.FORSCIINT.2005.04.022PMID 15979834
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine.

  2004cited by this paper
• Identification of 2,5-dimethoxy-4-ethylthiophenethylamine and its metabolites in the urine of rats by gas chromatography-mass spectrometry.

  2003cited by this paper
• New designer drug p-methoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry.

  2003cited by this paper
• In vivo metabolism of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites.

  2002cited by this paper
• [Explanation of an unclear neurological syndrome by toxicologic investigation].

  2000cited by this paper
• Aufklärung eines unklaren neurologischen Syndroms durch toxikologische Untersuchungen

  2000cited by this paper
• Toxicological analysis of whole blood samples by means of Bond-Elut Certify columns and gas chromatography with nitrogen-phosphorus detection.

  1994cited by this paper
• PIHKAL: A Chemical Love Story

  1991cited by this paper
• The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration.

  1990cited by this paper
• Mammalian metabolism of plant xenobiotics

  1978cited by this paper

• Triggers of Highly Lethal Seizures Induced by Novel Stimulants: A Systematic Review Focused on Synthetic Cathinones and Phenethylamines.

  2026cites this paper
• The State of the Art in Post-Mortem Redistribution and Stability of New Psychoactive Substances in Fatal Cases: A Review of the Literature

  2024cites this paper
• Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022).

  2024cites this paper
• Stimulant and hallucinogenic novel psychoactive substances; an update

  2023cites this paper
• Synthetic amphetamine derivatives, benzofurans, and benzodifurans

  2022cites this paper
• Analytical techniques for the detection of novel psychoactive substances and their metabolites

  2022cites this paper
• Safer Tripping: Serotonergic Psychedelics and Drug Checking. Submission and Detection Rates, Potential Harms, and Challenges for Drug Analysis

  2021cites this paper
• Psychonauts' psychedelics: A systematic, multilingual, web-crawling exercise.

  2021cites this paper
• A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines

  2020cites this paper
• Acute DOB and PMA Administration Impairs Motor and Sensorimotor Responses in Mice and Causes Hallucinogenic Effects in Adult Zebrafish

  2020cites this paper
• New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues

  2019cites this paper
• New psychoactive substances (NPS) prevalence over LSD in blotter seized in State of Santa Catarina, Brazil: A six-year retrospective study.

  2019cites this paper
• Prolonged Psychosis With Catatonia due to 2,5-Dimethoxy-4-Bromoamphetamine: Case Report and Literature Review.

  2019cites this paper
• Sympathomimetic Toxidromes and Other Pharmacological Causes of Acute Hypertension

  2018cites this paper
• Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens.

  2017cites this paper
• 2,5-dimethoxy-4-chloroamphetamine, a LSD-like designer drug: Clinical and analytical documentation of non-fatal exposure in five patients

  2017cites this paper
• The Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish

  2017cites this paper
• The detection and prevention of unintentional consumption of DOx and 25x‐NBOMe at Portugal's Boom Festival

  2017cites this paper
• A literature review of blood concentrations of new psychoactive substances classified as phenethylamines, aminoindanes, arylalkylamines, arylcyclohexylamines, and indolalkylamines.

  2017cites this paper
• Psychedelics

  2016cites this paper
• Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors

  2016cites this paper
• Identification and quantitation of 4-bromo-2,5-dimethoxyamphetamine in seized blotters.

  2015cites this paper
• Acid–Base Balance in the Poisoned Patient

  2015cites this paper
• Cross-reactivity of designer drugs, including cathinone derivatives, in commercial enzyme-linked immunosorbent assays.

  2014cites this paper
• Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse.

  2014cites this paper
• Designer Psychostimulants in Urine by Liquid Chromatography–Tandem Mass Spectrometry ,

  2014cites this paper
• „Legal highs“

  2014cites this paper
• Limitations of Drugs of Abuse Testing

  2013cites this paper
• Comprehensive forensic toxicological analysis of designer drugs

  2013influential citation
• Synthetic Amphetamine Derivatives

  2013cites this paper
• Psychoactive Phenethylamine, Piperazine, and Pyrrolidinophenone Derivatives

  2012cites this paper
• Drugs of Abuse (Including Designer Drugs)

  2012cites this paper
• Simultaneous detection of ten psychedelic phenethylamines in urine by gas chromatography-mass spectrometry.

  2011cites this paper
• Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents

  2011cites this paper
• Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept

  2011cites this paper
• Evaluation of commercial enzyme-linked immunosorbent assays to identify psychedelic phenethylamines.

  2011cites this paper
• Clinical toxicology of newer recreational drugs

  2011cites this paper
• Metabolism of designer drugs of abuse: an updated review.

  2010cites this paper
• LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum

  2010influential citation
• Simultaneous and group determination methods for designated substances by HPLC with multi-channel electrochemical detection and their application to real samples.

  2010cites this paper
• Bioanalysis of new designer drugs.

  2010cites this paper
• Analytical Toxicology of Emerging Drugs of Abuse

  2010cites this paper
• Chemistry, Pharmacology, and Metabolism of Emerging Drugs of Abuse

  2010cites this paper
• Advantages, disadvantages and limitations of immunochemical assays in analytical toxicology

  2009cites this paper
• Rapid, sensitive and simultaneous determination of fluorescence-labeled designated substances controlled by the Pharmaceutical Affairs Law in Japan by ultra-performance liquid chromatography coupled with electrospray-ionization time-of-flight mass spectrometry

  2009cites this paper
• Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY

  2009cites this paper
• Het gebruik van overige Tripmiddelen

  2008cites this paper
• Designer drug 2,5-dimethoxy-4-methyl-amphetamine (DOM, STP): involvement of the cytochrome P450 isoenzymes in formation of its main metabolite and detection of the latter in rat urine as proof of a drug intake using gas chromatography-mass spectrometry.

  2008cites this paper
• Metabolism and toxicological detection of a new designer drug, N-(1-phenylcyclohexyl)propanamine, in rat urine using gas chromatography-mass spectrometry.

  2008cites this paper
• 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.

  2008cites this paper
• New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.

  2008cites this paper
• Metabolism and toxicological detection of the designer drug N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA) in rat urine using gas chromatography-mass spectrometry.

  2008cites this paper
• Metabolism and toxicological detection of the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas chromatography-mass spectrometry

  2008cites this paper
• Simultaneous determination of 11 designated hallucinogenic phenethylamines by ultra-fast liquid chromatography with fluorescence detection.

  2008cites this paper
• Chapter 12 Forensic screening with GC-MS

  2008cites this paper
• The 2,5-dimethoxyamphetamines — a new class of designer drugs : studies on the metabolite identification, toxicological analysis, involvement of cytochrome P450 isoforms in main metabolic steps, and inhibition potentials on cytochrome P450 2D6

  2008cites this paper
• Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses.

  2007cites this paper
• Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) in rat urine using gas chromatography-mass spectrometry.

  2007cites this paper
• Metabolism and toxicological detection of the designer drug 4-iodo-2,5-dimethoxy-amphetamine (DOI) in rat urine using gas chromatography-mass spectrometry.

  2007cites this paper
• Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose

  2007cites this paper
• Chemical identification of 2,5-dimethoxy-4-bromoamphetamine (DOB).

  2007cites this paper
• New designer drug N-(1-phenylcyclohexyl)-3-ethoxypropanamine (PCEPA): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.

  2006cites this paper
• Designer drugs 2,5-dimethoxy-4-bromo-amphetamine (DOB) and 2,5-dimethoxy-4-bromo-methamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.

  2006cites this paper
• Designer drug 2,4,5-trimethoxyamphetamine (TMA-2): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.

  2006influential citation
• Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl-beta- phenethylamine (2C-D) in rat urine using gas chromatographic/mass spectrometric techniques.

  2006cites this paper
• New designer drug 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques.

  2006cites this paper
• Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy-beta-phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques.

  2006cites this paper
• Hyphenated mass spectrometric techniques-indispensable tools in clinical and forensic toxicology and in doping control.

  2006cites this paper
• Studies on the metabolism and toxicological detection of the designer drug 2,5‐dimethoxy‐4‐methyl‐β‐ phenethylamine (2C‐D) in rat urine using gas chromatographic/mass spectrometric techniques

  2006cites this paper
• Study on metabolites of 2,5-dimethoxy-4-bromamphetamine (DOB) in human urine using gas chromatography-mass spectrometry.

  2005cites this paper
• ZAOSTŘENO NA DROG Y 4

  2004cites this paper